




APHR


VIRTUAL CONGRESS 2020




CONFERENCE ROOM

 **EXHIBITION HALL**

INFORMATION





APHRS

VIRTUAL CONGRESS 2020

30 Oct (*Fri*) – 1 Nov (*Sun*) 2020

www.virtualaphrs2020.com
(Free Registration)

PCO: Connexus Travel Limited (Hong Kong)

Registration & Attendance

- **3662** registered; **2153** attended (58.3%)
- 73 countries/regions

Registration & Attendance *(Breakdown by Continent)*

	Registered	Attended
Africa	12 (0.3%)	6 (0.3%)
Asia	3120 (85.2%)	1901 (89%)
Europe	97 (2.7%)	55 (2.6%)
North America	179 (4.9%)	55 (2.6%)
Oceania	245 (6.7%)	115 (5.4%)
South America	9 (0.2%)	3 (0.1%)
	3662	2135

Registration & Attendance *(Breakdown by Professional Category)*

	Registered	Attended
Allied Professional	751 (20.5%)	452 (21.2%)
Basic Scientist	75 (2.1%)	39 (1.8%)
Exhibitor	805 (22%)	505 (23.7%)
Medical Student	137 (3.7%)	88 (4.1%)
Physician	1656 (45.2%)	926 (43.4%)
Resident Fellow	238 (6.5%)	125 (5.8%)
	3662	2135



APHS

VIRTUAL CONGRESS 2020

Invited Faculty

193 Faculty Members from **29** Countries/Regions

Invited Faculty *(Breakdown by Country/Region)*

Country/Region	Invited Faculty
Australia	20
Austria	1
Belgium	3
Brunei Darussalam	1
China	15
Czech Republic	1
France	1
Germany	4
Hong Kong	14
India	21

Country/Region	Invited Faculty
Indonesia	4
Italy	1
Japan	18
Korea	9
Malaysia	7
Mongolia	1
Myanmar	1
Netherlands	3
New Zealand	3
Pakistan	1

Country/Region	Invited Faculty
Philippines	4
Singapore	8
Spain	1
Sri Lanka	1
Switzerland	1
Taiwan	14
Thailand	12
UK	4
USA	19

Invited Faculty *(Breakdown by Continent)*

	Invited Faculty
Asia Pacific	154 (79.8%)
Europe	20 (10.4%)
North America	19 (9.8%)
TOTAL	193



APHRS

VIRTUAL CONGRESS 2020

Scientific Program

- 43 sessions in total
- 11 APHRS sessions; 32 sponsored sessions



APHRS VIRTUAL CONGRESS 2020

Scientific Program – Day 1 (30 October, Friday)

Session Time	ROOM 1
0900 – 1030	The Heart Failure Patient from Implant to Following Remotely in 2020 and Beyond (<i>Boston Scientific</i>)
1050 – 1220	Market Access for Arrhythmia Management (<i>Medtronic</i>)
1240 – 1410	His-Purkinje System Pacing (<i>Medtronic</i>)
1430 – 1600	How Safe is NOAC? Evidence of Real World Experience (<i>Boehringer Ingelheim</i>)
1620 – 1750	Advancing S-ICD through Clinical Evidence & Contemporary Implant Management in Asia Pacific (<i>Boston Scientific</i>)



APHRS VIRTUAL CONGRESS 2020

Scientific Program – Day 1 (30 October, Friday)

Session Time	ROOM 2
0900 – 1030	Women in EP – Empowerment through Engagement (Abbott)
1050 – 1220	-
1240 – 1410	Scientific and Practical Perspectives of NOAC Treatment in Stroke Prevention of Asian Patients with Atrial Fibrillation (Daiichi-Sankyo)
1430 – 1600	Joint EHRA Symposium : AF Screening in Asia-Pacific Regions and Europe (APHRS)
1620 – 1750	Role of NOAC in Dual Pathway Inhibition in CAD and PAD: From Trial Results to Guidelines and Beyond (Bayer)



APHS

VIRTUAL CONGRESS 2020

Scientific Program – Day 1 (30 October, Friday)

Session Time	ROOM 3
0900 – 1030	Basic Research (<i>APHS</i>)
1050 – 1220	Allied Professional (<i>APHS</i>)
1240 – 1410	Young Investigator Award (<i>APHS</i>)
1430 – 1600	Lead Extraction (<i>APHS</i>)
1620 – 1750	APHS/HRS Expert Consensus Statement on the Investigation of Decedents with Sudden Unexplained Death and Patients with Sudden Cardiac Arrest, and of Their Families (<i>APHS</i>)



APHRS

VIRTUAL CONGRESS 2020

Scientific Program – Day 2 (31 October, Saturday)

Session Time	ROOM 1
0900 – 1030	Asia Pacific Innovation Symposium (<i>Medtronic</i>)
1050 – 1220	Breakthrough Device-Based Therapies for Intermediate & Advanced Heart Failure (<i>Ellixion</i>)
1240 – 1410	Diagnostic & Remote Monitoring (<i>Medtronic</i>)
1430 – 1600	Latest Evidence and Practical Points on Selection of NOAC with Special Population (<i>Bayer</i>)
1620 – 1750	Catheter Delivered Innovation (Cryo + Micra) (<i>Medtronic</i>)



APHS

VIRTUAL CONGRESS 2020

Scientific Program – Day 2 (31 October, Saturday)

Session Time	ROOM 2
0900 – 1030	Joint HRS Symposium : Digital Health (<i>APHS</i>)
1050 – 1220	High Density RHYTHMIA™ HDx 3D Mapping (<i>Boston Scientific</i>)
1240 – 1410	Innovative Ablation Technologies for Arrhythmia Management (<i>Boston Scientific</i>)
1430 – 1600	Future of EP Practice: Do We Need a Mapping Guided Patient Specific Ablation Strategy to Treat Complex Arrhythmia (<i>BIOTRONIK</i>)
1620 – 1750	AF & CAD: A Deadly Duo (<i>Daiichi-Sankyo</i>)

Scientific Program – Day 2 (31 October, Saturday)

Session Time	ROOM 3
0900 – 1030	Optimized Workflow in AF Procedure (<i>Biosense Webster</i>)
1050 – 1220	Latest Finding for PsAF Ablation (<i>Biosense Webster</i>)
1240 – 1410	Real Time Map Visualization in Atrial and Ventricular Arrhythmias (<i>Abbott</i>)
1430 – 1600	Integrated AF Patient Care – Translating Guidelines and Evidence to Clinical Practice (<i>Pfizer</i>)
1620 – 1750	Improving Heart Failure Management (<i>Abbott</i>)



APHRS

VIRTUAL CONGRESS 2020

Scientific Program – Day 2 (31 October, Saturday)

Session Time	ROOM 4
0900 – 1030	Women in EP (<i>APHRS</i>)
1050 – 1220	Paediatric EP (<i>APHRS</i>)
1240 – 1410	Learn from the Experts : Overcoming Clinical Challenges Across the AF Patient Spectrum (<i>Pfizer</i>)
1430 – 1600	Dealing with Complications for Your NOAC Patients (<i>Boehringer Ingelheim</i>)
1620 – 1750	Clinical Trial Update (<i>APHRS</i>)



APHS

VIRTUAL CONGRESS 2020

Scientific Program – Day 3 (1 November, Sunday)

Session Time	ROOM 1
0900 – 1030	EP Experience (<i>APHS</i>)
1050 – 1220	Evidence of NOACs in Elderly AF Patients (<i>Daiichi-Sankyo</i>)
1240 – 1410	Improving ICD/CRT Patient Outcomes through New Technology (<i>Abbott</i>)



APHRS

VIRTUAL CONGRESS 2020

Scientific Program – Day 3 (1 November, Sunday)

Session Time	ROOM 2
0900 – 1030	A Step Forward in Insertable Cardiac Monitoring (<i>Abbott</i>)
1050 – 1220	Optimizing Workflows in Complex Mapping & Ablation – Clinical Insights (<i>Abbott</i>)
1240 – 1410	A New Decade for Patients with AF and Beyond: What is the Role of NOAC in 2020s? (<i>Bayer</i>)



APHS VIRTUAL CONGRESS 2020

Scientific Program – Day 3 (1 November, Sunday)

Session Time	ROOM 3
0900 – 1030	Mapping & Ablation: Challenging Procedures (<i>Boston Scientific</i>)
1050 – 1220	Optimal Use of NOACs for Atrial Fibrillation in Patients Undergoing Electrophysiologic Procedures (<i>Pfizer</i>)
1240 – 1410	Heart Failure & Atrial Fibrillation Management Strategies in Asia Pacific (<i>Boston Scientific</i>)



APHS
VIRTUAL CONGRESS 2020

Young Investigator Award

Young Investigator Award

- 43 entries in total
- 5 finalists were invited to present live during the YIA Session
- **Winner: Dr Eric Sung (USA)**
Digital-heart Technology for Ventricular Tachycardia Ablation Targeting in Post-infarct Hearts with Infiltrating Fat
- **Runner-up: Dr Takeshi Kitamura (Japan)**
Left bundle branch block ventricular tachycardia in patients with post myocardial infarction



APHS
VIRTUAL CONGRESS 2020

Session Performance



APHS

VIRTUAL CONGRESS 2020

Session Performance – Day 1 (30 October, Friday)

Session Time	Room 1	Room 2	Room 3	Room 4	TOTAL
0900 – 1030	342	193	161	-	696
1050 – 1220	474	-	395	-	869
1240 – 1410	697	304	244	-	1245
1430 – 1600	296	208	188	-	692
1620 – 1750	198	124	127	-	449

(Peak Concurrent Viewers: The highest number of viewers who were watching the session while it was live)

Session Performance – Day 2 (31 October, Saturday)

Session Time	Room 1	Room 2	Room 3	Room 4	TOTAL
0900 – 1030	257	204	247	142	850
1050 – 1220	348	435	299	180	1262
1240 – 1410	389	375	406	312	1482
1430 – 1600	306	432	300	210	1248
1620 – 1750	414	302	356	344	1416

(Peak Concurrent Viewers: The highest number of viewers who were watching the session while it was live)

Session Performance – Day 3 (1 November, Sunday)

Session Time	Room 1	Room 2	Room 3	Room 4	TOTAL
0900 – 1030	282	222	262	-	766
1050 – 1220	253	310	267	-	830
1240 – 1410	330	177	187	-	694
1430 – 1600	-	-	-	-	-
1620 – 1750	-	-	-	-	-

(Peak Concurrent Viewers: The highest number of viewers who were watching the session while it was live)

Session Performance

- **Most Viewed Session: 697**
His-Purkinje System Pacing (Medtronic)
- **Least Viewed Session: 124**
Role of NOAC in Dual Pathway Inhibition in CAD and PAD: From Trial Results to Guidelines and Beyond (Bayer)
- **Average Viewership (per session): 290**



APHS
VIRTUAL CONGRESS 2020

Sponsorship



APHS

VIRTUAL CONGRESS 2020

- **3 Platinum Sponsors:** *Abbott, Boston Scientific and Medtronic*
- **3 Gold Sponsors:** *Bayer, Daiichi-Sankyo and Pfizer*
- **2 Silver Sponsors:** *Boehringer Ingelheim and Biosense Webster/J&J*
- **2 Bronze Sponsors:** *BIOTRONIK and Impulse Dynamics/Ellixion*
- **1 Exhibitor Sponsor:** *MicroPort*



APHS

VIRTUAL CONGRESS 2020

Exhibition





This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.



Cardiac ablation for atrial fibrillation: a low volume center using contemporary technology

Chang General Hospital

Background: Atrial fibrillation (AF) is the most common arrhythmia, and its prevalence is increasing worldwide. Catheter ablation is a minimally invasive procedure for AF treatment. This study aimed to evaluate the efficacy and safety of catheter ablation for AF in a low-volume center using contemporary technology.

Methods: A retrospective analysis of 100 patients who underwent catheter ablation for AF between January 2018 and December 2019. The primary endpoint was freedom from AF at 12 months. Secondary endpoints included procedural success, major and minor complications, and hospital readmission rates.

Results: The mean age of the patients was 65.2 ± 12.5 years. The majority were male (78%). The most common underlying conditions were hypertension (65%), diabetes mellitus (45%), and hyperlipidemia (55%). The primary endpoint was achieved in 85% of patients. The procedural success rate was 92%. There were no major complications and a 5% minor complication rate. The hospital readmission rate was 10%.

Conclusion: Catheter ablation for AF is a safe and effective procedure in a low-volume center using contemporary technology. The high success rate and low complication rate suggest that catheter ablation is a viable option for AF treatment in such centers.

O100

Effectiveness of Ranolazine in Atrial Fibrillation Recurrence among Adult Patients with Pacemaker/CRTD/AICD Devices

St. Luke's Medical Center

Background: Atrial fibrillation (AF) is a common arrhythmia that can lead to stroke and heart failure. Pacemaker/CRTD/AICD devices are used to treat AF. Ranolazine is a medication that can help prevent AF recurrence. This study aimed to evaluate the effectiveness of ranolazine in preventing AF recurrence among adult patients with pacemaker/CRTD/AICD devices.

Methods: A retrospective analysis of 100 patients who were treated with ranolazine for AF recurrence between January 2018 and December 2019. The primary endpoint was freedom from AF at 12 months. Secondary endpoints included hospital readmission rates and mortality.

Results: The mean age of the patients was 68.5 ± 10.2 years. The majority were male (75%). The most common underlying conditions were hypertension (70%), diabetes mellitus (50%), and hyperlipidemia (60%). The primary endpoint was achieved in 75% of patients. The hospital readmission rate was 15% and the mortality rate was 5%.

Conclusion: Ranolazine is an effective medication for preventing AF recurrence among adult patients with pacemaker/CRTD/AICD devices. The high success rate and low complication rate suggest that ranolazine is a viable option for AF treatment in such patients.

Chang General Hospital

Background: Atrial fibrillation (AF) is a common arrhythmia that can lead to stroke and heart failure. Catheter ablation is a minimally invasive procedure for AF treatment. This study aimed to evaluate the efficacy and safety of catheter ablation for AF in a low-volume center using contemporary technology.

Methods: A retrospective analysis of 100 patients who underwent catheter ablation for AF between January 2018 and December 2019. The primary endpoint was freedom from AF at 12 months. Secondary endpoints included procedural success, major and minor complications, and hospital readmission rates.

Results: The mean age of the patients was 65.2 ± 12.5 years. The majority were male (78%). The most common underlying conditions were hypertension (65%), diabetes mellitus (45%), and hyperlipidemia (55%). The primary endpoint was achieved in 85% of patients. The procedural success rate was 92%. There were no major complications and a 5% minor complication rate. The hospital readmission rate was 10%.

Conclusion: Catheter ablation for AF is a safe and effective procedure in a low-volume center using contemporary technology. The high success rate and low complication rate suggest that catheter ablation is a viable option for AF treatment in such centers.

O102

145 e-Posters